Keywords:
dyslipidemia, cholesterol, LDL-C, complications.References
Amlayev K.R. Dyslipidemias: epidemiology, clinical aspects, diagnosis, prevention and treatment. Vrach. 2021; 32 (5): 16–20. https://doi.org/10.29296/25877305-2021-05-03.
Baranova E.I. et al., edited by Shlyakhto E.V. Modern principles of diagnosis and treatment of dyslipidemias: study guide. St. Petersburg: RIC PSPbGMU, 2020. – p. ISBN.
Konradi A.O., Alieva A.S. (2021). Arterial hypertension and dyslipidemia. Parallel control of two risk factors – the role of drug combinations. Arterial Hypertension, 27 (3), 376–383.
Metelskaya V.A., Shalnova S.A., Deev A.D. et al. Analysis of the prevalence of indicators characterizing the atherogenicity of the lipoprotein spectrum in the population of the Russian Federation (according to the ESSE-RF study). Preventive Medicine. 2016;19(1):15–23. doi:10.17116/profmed201619115-23.
Thongtang N, Sukmawan R, Llanes EJB, Lee ZV. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Prev Med Rep. 2022 May 5;27:101819. doi: 10.1016/j.pmedr.2022.101819. PMID: 35656215; PMCID: PMC9152805.
World Health Organization. The global health observatory. Available from: https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3236. Accessed De-cember 31, 2022.